Rosuvastatin + ezetimibe

Intervention Approved 2021

3 papers4 findings

PubChem 446157 PubChem 150311 ChEBI 38545 ChEBI 49040

Human studies report lower LDL cholesterol: a preprint in virologically stable people with HIV also reports improved cardiovascular risk scores, and a trial in males with homozygous familial hypercholesterolaemia reports reduced xanthomas. Work spans 2 independent labs in 1 country; 19 of 37 registered trials ended over a year ago without posted results or citing papers.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 1 country
37 trials, 19 with no results posted

Humans1

Outcomes

Xanthomas

downin humans1

1 study

Rosuvastatin + ezetimibe decreases xanthomas in humans.
Human trialhomozygous familial hypercholesterolemiamales
Early Coronary Atherosclerosis in Homozygous Familial Hypercholesterolemia: The Importance of Aggressive Lipid Lowering
JACC. Case reports10 Sep 2026

Low-density lipoprotein cholesterol

downin humans1

1 study

Rosuvastatin + ezetimibe decreases low-density lipoprotein cholesterol in humans (to 235 mg/dL from baseline 663 mg/dL).
Human trialhomozygous familial hypercholesterolemiamales
Early Coronary Atherosclerosis in Homozygous Familial Hypercholesterolemia: The Importance of Aggressive Lipid Lowering
JACC. Case reports10 Sep 2026

More on Low-density lipoprotein cholesterol

CVD risk score

upin humans1

1 study

Rosuvastatin + ezetimibe improves CVD risk score in humans.
“CVD risk scores improved and correlated with LDL-C reduction (D:A:D, r=0.74).”
Humansin PLWHfixed-dose combinationrosuvastatin 5 mg plus ezetimibe 10 mg daily6 monthsn = 32
Optimizing Cardiovascular Risk in PLWH: Real-World Efficacy and Lipid Kinetics of Fixed-Dose Combination Rosuvastatin/Ezetimibe
Preprints.org2 Sep 2026Preprint